In 2015, ASCO and AACI led a multi-stakeholder survey to identify and prioritize the most burdensome regulatory and/or administrative aspects of clinical trials: clinical trial contracting, clinical trial coverage analyses and budgeting, and training and regulatory requirements.
As part of ASCO’s efforts to support cancer researchers and research sites, the ASCO Research Community Forum was created in 2010 to help clinical investigators and research staff overcome common barriers to conducting research and enhance their research site operations.
Clinical trials remain the backbone of cancer therapies, but participation in trials has remained at low levels for decades. In several Education Sessions, experts will discuss overcoming barriers to clinical trial participation, the importance of Cooperative Group trials, and related topics.
For pioneering several cancer treatment methodologies, Dr. Waun Ki Hong will be honored with the 2016 Special Recognition Award, given to individuals who have had a major influence in the areas of clinical oncology, cancer research, clinical trials, reimbursement, and patient advocacy activities.
Drs. Beverly A. Teicher, Francisco J. Esteva, and Kathy Miller to present the past, present, and future of antibody-drug conjugates for the management of solid and hematologic malignancies. Their discussion will review past clinical studies and future application in the clinical setting.
Dr. Matthew J. Ellis will receive the ASCO 2015 Gianni Bonadonna Breast Cancer Award and Lecture for his pioneering research into the clinical relevance of activating mutations in HER2 and in the deployment of patient-derived xenografts for the pharmacological annotation of breast cancer genomes.
Plans were announced Monday for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study and the National Cancer Institute (NCI)-MATCH: Molecular Analysis for Therapy Choice trial (EAY131), two clinical studies which aim to expand the boundaries of precision medicine.
In patients with previously untreated HER2-positive metastatic breast cancer, T-DM1 appears to be noninferior to trastuzumab plus a taxane but is not superior to HT, and the addition of pertuzumab to T-DM1 offers no efficacy benefit, based on results of the randomized, phase III MARIANNE trial.
One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of the randomized ExteNET trial.